Biomarker Assessment in Parkinson's Disease Dementia and Dementia with Lewy Bodies by the Immunomagnetic Reduction Assay and Clinical Measures.

Document Type

Article

Abstract

BACKGROUND: Plasma biomarker assays provide an opportunity to reassess whether Alzheimer's disease, Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB) plasma biomarkers are diagnostically useful.

OBJECTIVE: We hypothesized that immunomagnetic reduction (IMR) of plasma biomarkers could differentiate between patients with PDD and DLB and healthy patients when combined with established clinical testing measures.

METHODS: Plasma samples from 61 participants (12 PDD, 12 DLB, 37 controls) were analyzed using IMR to quantify amyloid-β 42 (Aβ

RESULTS: Participants with PDD had higher α-syn than those with DLB and healthy participants and were distinguishable by their biomarker products Aβ

CONCLUSIONS: In this pilot study, IMR plasma p-tau181 and α-syn may discriminate between PDD and DLB when used in conjunction with clinical testing.

Publication Date

1-1-2024

Publication Title

J Alzheimers Dis Rep

ISSN

2542-4823

Volume

8

Issue

1

First Page

1361

Last Page

1371

PubMed ID

39493956

Digital Object Identifier (DOI)

10.3233/ADR-240110

This document is currently not available here.

Share

COinS